How do you steer your patients through the threat of EBV+ PTLD?
Epstein-Barr virus–positive post-transplant lymphoproliferative disease (EBV+ PTLD) is a life-threatening malignancy that presents challenges in the management of transplant patients.
Share your experience and see how other clinicians have responded
Atara Biotherapeutics, Inc.
611 Gateway Blvd, Suite 900
South San Francisco, CA 94080
Atara Biotherapeutics Switzerland GmbH
Baarerstrasse 14-16
6300 Zug, Switzerland
Copyright © 2019 Atara Biotherapeutics. All Rights Reserved. US -1800006 12/2019